These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents. Steensma DP Am J Hematol; 2008 Sep; 83(9):693-4. PubMed ID: 18615451 [No Abstract] [Full Text] [Related]
4. [Research methodology: A guarantee for progress in knowledge about infections]. Carballo Alvarez F Rev Esp Quimioter; 2001 Jun; 14(2):126-37. PubMed ID: 11704767 [No Abstract] [Full Text] [Related]
5. [Clinical experimental research in hematology: planning, data management and the presentation of the results]. Kulikov SM; Savchenko VG; Maslova ER; Parovichnikova EN; Gudulina IuIu Ter Arkh; 1996; 68(7):65-72. PubMed ID: 8928076 [No Abstract] [Full Text] [Related]
6. Research outcomes and recommendations for the assessment of progression in cancer clinical trials. Bushnell W; Stone A J Biopharm Stat; 2013; 23(5):949-50. PubMed ID: 23957508 [No Abstract] [Full Text] [Related]
7. Preferred designs, outcomes, and analysis strategies for treatment trials in idiopathic recurrent acute pancreatitis. Romagnuolo J; Guda N; Freeman M; Durkalski V Gastrointest Endosc; 2008 Nov; 68(5):966-74. PubMed ID: 18725158 [No Abstract] [Full Text] [Related]
8. The art of choosing sound study endpoints. Hanson B Injury; 2008 Jun; 39(6):656-8. PubMed ID: 18514657 [TBL] [Abstract][Full Text] [Related]
9. Interpretation of clinical trial results. Practice Committee of American Society for Reproductive Medicine Fertil Steril; 2008 Nov; 90(5 Suppl):S114-20. PubMed ID: 19007606 [TBL] [Abstract][Full Text] [Related]
11. [Randomization and comparison of final quality in clinical studies]. Altman DG; Doré CJ Z Arztl Fortbild Qualitatssich; 2005; 99(10):629-34. PubMed ID: 16433266 [No Abstract] [Full Text] [Related]
13. Health-related quality of life and cancer. Bottomley A Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):9-11. PubMed ID: 19371172 [No Abstract] [Full Text] [Related]
14. [Inclusion of health-related quality of life studies alongside clinical trials: basis and practical recommendations. Utilization of a check-list for their correct desing and evaluation]. Soto Alvarez J An Med Interna; 2003 Dec; 20(12):633-44. PubMed ID: 14697086 [No Abstract] [Full Text] [Related]
16. Comments on 'Current issues in non-inferiority trials' by Thomas R. Fleming, Statistics in Medicine, DOI: 10.1002/sim.2855. Koch GG Stat Med; 2008 Feb; 27(3):333-42. PubMed ID: 17530625 [No Abstract] [Full Text] [Related]
17. Performing serial testing of treatment effects. Fleming TR; Green SJ; Harrington DP Experientia Suppl; 1982; 41():469-84. PubMed ID: 6958531 [No Abstract] [Full Text] [Related]
18. The importance of determining quality of life in clinical trials. Temple L; Fuzesi S; Patil S Surgery; 2009 Jun; 145(6):622-6. PubMed ID: 19486762 [No Abstract] [Full Text] [Related]
19. Large trials, small gains: is change on the way? Tuma RS J Natl Cancer Inst; 2010 Aug; 102(16):1216-17, 1223. PubMed ID: 20693460 [No Abstract] [Full Text] [Related]
20. Designing clinical trials in amyotrophic lateral sclerosis. Shefner JM Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):495-508, ix. PubMed ID: 18625412 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]